32 patents currently held
62 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
1 more record may belong here and awaits a decision; it is not counted.
The next term ends in Oct 2028. from the record
Of the 62 now held by other companies, 11 were conveyed to Alector LLC in the filing they arrived in, and 51 more name another party. Each row says which.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
7
Ending by 2030
Oct 2028
Next term end
16
Patent families
When these terms end
Held patents by the year their term ends
notable patents
all others
Updated Nov 14, 2026 · includes USPTO assignment & status data published Nov 14, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Dec 2029 · High confidence
Also notable
Ends Nov 2035 · High confidence
Also notable
Ends Nov 2035 · High confidence
Rationally Designed, Synthetic Antibody Libraries and Uses Therefor
US 8,691,730
The most cited patent in this portfolio, cited by 110 later US patents, top 5% of utility patents granted in 2014 in our data. Protection runs to 2029.
Anti-Transferrin Receptor / ANTI-BACE1 Multispecific Antibodies and Methods of Use
US 11,008,403
Cited by 8 later US patents, top 25% of utility patents granted in 2021 in our data. Protection runs to 2035.
Antibodies Against BACE1 and Use Thereof for Neural Disease Immunotherapy
US 10,882,920
Cited by 6 later US patents, top 25% of utility patents granted in 2021 in our data. Protection runs to 2035.
Formerly held, still cited
Notable
Ends Apr 2036 · High confidence
Methods of Use of Anti-Sortilin Antibodies for Treating a Disease, Disorder, or Injury
US 11,339,223
Cited by 7 later US patents, top 25% of utility patents granted in 2022 in our data. Protection runs to 2036.
conveyed to Alector LLC
Also notable
Ends Jul 2038 · Low confidence
Cited by 19 later US patents, top 25% of utility patents granted in 2019 in our data, and renewed at 2 of 3 maintenance windows. Protection runs to 2038. A terminal disclaimer caps this term to an earlier patent's.
conveyed to Compass Therapeutics LLC
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Mar 5, 2027The maintenance fee for Antibodies Against BACE1 and Use Thereof for Neural Disease Immunotherapy (US 11,746,160) comes due Mar 5, 2027. Unpaid by Sep 7, 2027, it lapses early.
Recent changes
- 2 of the patents on this record were granted since Aug 16, 2026
What they patent
The 5 largest of its 16 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
| Rationally Designed, Synthetic Antibody Libraries and Uses Therefor | 7 in force | to Sep 2030 |
| Antibody Libraries | 4 in force | to Oct 2032 |
| Polyclonal Mixtures of Antibodies, and Methods of Making and Using Them | 3 in force | to Aug 2037 |
| Polyspecificity Reagents, Methods for Their Preparation and Use | 3 in force | to Nov 2035 |
| Anti-Respiratory Syncytial Virus Antibodies, and Methods of Their Generation and Use | 2 in force | to Nov 2038 |
Patents held now
Soonest term end first.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 11,008,568 | Rationally Designed, Synthetic Antibody Libraries and Uses Therefor In force · High confidence | In force | High confidence | |
| US 12,529,164 | Rationally Designed, Synthetic Antibody Libraries and Uses Therefor In force · Medium confidence | In force | Medium confidence | |
| US 11,008,383 | Rationally Designed, Synthetic Antibody Libraries and Uses Therefor In force · High confidence | In force | High confidence | |
| US 10,196,635 | Rationally Designed, Synthetic Antibody Libraries and Uses Therefor In force · Medium confidence | In force | Medium confidence | |
| US 8,691,730 | Rationally Designed, Synthetic Antibody Libraries and Uses Therefor In force · High confidence | In force | High confidence | |
| US 10,189,894 | Rationally Designed, Synthetic Antibody Libraries and Uses Therefor In force · High confidence | In force | High confidence | |
| US 8,877,688 | Rationally Designed, Synthetic Antibody Libraries and Uses Therefor In force · Medium confidence | In force | Medium confidence | |
| US 10,138,478 | Antibody Libraries In force · High confidence | In force | High confidence | |
| US 10,889,811 | Antibody Libraries In force · High confidence | In force | High confidence | |
| US 12,018,403 | Antibody Libraries In force · High confidence | In force | High confidence |
Also on record, not counted in the 32: 62 patents in force now held by others · 6 patents ended · 39 applications pending · 34 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.